Literature DB >> 17044048

Neuroblastoma tumors with favorable and unfavorable outcomes: Significant differences in mRNA expression of genes mapped at 1p36.2.

Susanne Fransson1, Tommy Martinsson, Katarina Ejeskär.   

Abstract

The distal part of 1p is frequently deleted in aggressive neuroblastoma, and the region is believed to harbor one or more tumor suppressor genes relevant to tumor development. To analyze differences among neuroblastoma tumors, an expression profile was established for the genes mapped within a previously described shortest region of overlap of deletions at 1p36.2. The gene expression levels were quantified by TaqMan real-time (RT)-PCR for 30 transcripts using 55 primary neuroblastoma tumors. Here we report on a significant decrease in gene expression of the genes RERE, PIK3CD, LZIC, PGD, and PEX14 and an increase of SLC2A5 when comparing tumors of favorable biology to Stage 4 neuroblastomas. When comparing 1p-deleted tumors of all stages to tumors with an intact 1p, a significant difference at gene-by-gene level in TNFRSF9, RERE, PIK3CD, CLSTN1, CTNNBIP1, and CASZ1 was detected. A complete loss of expression could not be seen for any single gene analyzed. Several of the genes with diminished expression in unfavorable or 1p-deleted tumors have functions that could contribute to tumor development. It is also possible that a combination of lowly expressed genes at 1p, rather than one single classical tumor suppressor gene, causes the unfavorable outcome associated with 1p-deletion in neuroblastoma. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17044048     DOI: 10.1002/gcc.20387

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

1.  High level of p37δ-mRNA relative to p110δ-mRNA in neuroblastoma tumors correlates with poor patient survival.

Authors:  Susanne Fransson; Katarina Ejeskär
Journal:  Med Oncol       Date:  2013-09-12       Impact factor: 3.064

2.  EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.

Authors:  Chunxi Wang; Zhihui Liu; Chan-Wook Woo; Zhijie Li; Lifeng Wang; Jun S Wei; Victor E Marquez; Susan E Bates; Qihuang Jin; Javed Khan; Kai Ge; Carol J Thiele
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

3.  Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.

Authors:  Andrea Cornero; Massimo Acquaviva; Paolo Fardin; Rogier Versteeg; Alexander Schramm; Alessandra Eva; Maria Carla Bosco; Fabiola Blengio; Sara Barzaghi; Luigi Varesio
Journal:  BMC Bioinformatics       Date:  2012-03-28       Impact factor: 3.169

4.  Quantitative analysis of human tissue-specific differences in methylation.

Authors:  Jun Igarashi; Satomi Muroi; Hiroyuki Kawashima; Xiaofei Wang; Yui Shinojima; Eiko Kitamura; Toshinori Oinuma; Norimichi Nemoto; Fei Song; Srimoyee Ghosh; William A Held; Hiroki Nagase
Journal:  Biochem Biophys Res Commun       Date:  2008-09-19       Impact factor: 3.575

5.  Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy.

Authors:  Amanda J Law; Yanhong Wang; Yoshitatsu Sei; Patricio O'Donnell; Patrick Piantadosi; Francesco Papaleo; Richard E Straub; Wenwei Huang; Craig J Thomas; Radhakrishna Vakkalanka; Aaron D Besterman; Barbara K Lipska; Thomas M Hyde; Paul J Harrison; Joel E Kleinman; Daniel R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-11       Impact factor: 11.205

Review 6.  The PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia.

Authors:  Lilian Enriquez-Barreto; Miguel Morales
Journal:  Mol Cell Ther       Date:  2016-02-11

7.  The Unique Non-Catalytic C-Terminus of P37delta-PI3K Adds Proliferative Properties In Vitro and In Vivo.

Authors:  Katarina Ejeskär; Oscar Vickes; Arunakar Kuchipudi; Yvonne Wettergren; Anne Uv; Victoria Rotter Sopasakis
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

8.  Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas.

Authors:  Susanne Fransson; Per Kogner; Tommy Martinsson; Katarina Ejeskär
Journal:  J Mol Signal       Date:  2013-04-18

9.  A constitutional translocation t(1;17)(p36.2;q11.2) in a neuroblastoma patient disrupts the human NBPF1 and ACCN1 genes.

Authors:  Karl Vandepoele; Vanessa Andries; Nadine Van Roy; Katrien Staes; Jo Vandesompele; Geneviève Laureys; Els De Smet; Geert Berx; Frank Speleman; Frans van Roy
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

10.  Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours.

Authors:  H Carén; S Fransson; K Ejeskär; P Kogner; T Martinsson
Journal:  Br J Cancer       Date:  2007-10-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.